Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × talazoparib × NET × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 8 Other solid neoplasm 6 Gynecologic 6 Thoracic 4 Other hematologic neoplasm 4 Genitourinary 4 Gastrointestinal 4 Tumor-Agnostic 2 Myeloid 2 Sarcoma 1 NET 1 Lymphoid 1 Head & Neck 1 Endocrine 1 Classical hematology 1

Conditions

Neuroendocrine Tumors 1

Interventions

Everolimus 8 lutetium Lu 177 dotatate 6 Magnetic Resonance Spectroscopy 6 Specimen Handling 3 Nivolumab 3 Fluorodeoxyglucose F18 3 pasireotide 2 olaparib 2 Positron Emission Tomography Computed Tomography 2 Ipilimumab 2 Ga(III)-DOTATOC 2 FAPI-46 2 (177)Lu-DOTA-EB-TATE 2 veliparib 1 toripalimab 1 tislelizumab 1 talazoparib 1 surufatinib 1 peposertib 1 pembrolizumab 1 gallium Ga 68 dotatate 1 fosbretabulin 1 fludarabine phosphate 1 exemestane 1 decitabine and cedazuridine drug combination 1 dactolisib 1 cabozantinib 1 amino-acid, glucose, and electrolyte solution 1 Tomography, X-Ray Computed 1 Tomography, Emission-Computed, Single-Photon 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05053854 2025-02-20

PARLuNET

Peter MacCallum Cancer Centre, Australia

Phase 1 Recruiting

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡